In prior studies, combining CpG and agonistic anti-OX40 antibody (OX40) was able to activate an in situ vaccine effect and generate substantial preclinical anti-tumor activity in some tumor models, including the A20 lymphoma model (9–11). This evidence concerns the gene TNFRSF4 and neoplasm.